Study Demonstrates Significant Clinical and Economic Impact of Nanosphere's Verigene Blood Culture Test

Study Demonstrates Significant Clinical and Economic Impact of Nanosphere's 
Verigene Blood Culture Test 
Average per Patient Hospital Cost Savings of $60,000 and 22 Day
Reduction in Length of Stay Observed 
NORTHBROOK, IL -- (Marketwired) -- 09/30/13 --  Nanosphere, Inc.
(NASDAQ: NSPH), a company enhancing medicine through targeted
molecular diagnostics, today announced publication of a study in the
Journal of Clinical Microbiology that evaluated the clinical and
economic impact of rapid bacterial identification and antibiotic
resistance determination by the Verigene(R) Gram-Positive Blood
Culture (BC-GP) Test for patients with enterococcal bacteremia, which
can lead to sepsis.  
The manuscript reports that following implementation of Verigene
BC-GP for the detection of bloodstream infections caused by
Enterococcus, there was an average per patient reduction in hospital
length of stay of 21.7 days, and an average savings of $60,729 in
hospital costs.  
In addition, there was a significant decrease in the average time it
took for patients to receive appropriate treatment (23.4 hours), and
an even greater reduction in time (31.1 hours) for patients with
vancomycin-resistant Enterococcus (VRE) bacteremia -- an especially
deadly cause of bloodstream infection and sepsis. Importantly,
Verigene results enabled clinicians to immediately select appropriate
therapy for 100 percent of patients with vancomycin-susceptible
Enterococcus (VSE) bacteremia, potentially resulting in further cost
savings.  
Finally, there was complete agreement between BC-GP test results and
those derived from conventional culture and susceptibility methods,
along with a significant reduction in time to reporting of test
results (47.5 hours).  
"Minimizing time to appropriate antimicrobial therapy permits more
effective targeting of the causative pathogens, decreases
antimicrobial exposure, and can result in cost avoidance," said
Yvette McCarter, PhD, D(ABMM), Director of Clinical Microbiology,
University of Florida Health Jacksonville. "Utilization of assays
such as the BC-GP test, supported by collaboration between
microbiology and pharmacy, can optimize antimicrobial use, decrease
unnecessary length of stay and costs, and improve time to appropriate
therapy." 
"We are very pleased with the study results as they demonstrate the
significant clinical and economic value of Verigene in equipping
antimicrobial stewardship teams with the information they need to
recommend the best course of treatment for their patients," said
Michael McGarrity, Nanosphere's president and chief executive
officer. "A recent CDC landmark report highlighted the importance of
improved antibiotic stewardship and the implementation of new
diagnostic tests to aid in addressing the problem of
antibiotic-resistant infections. As demonstrated in this study,
Verigene has the ability to help hospitals meet this critical need,
and the potential to improve patient outcomes, optimize antibiotic
therapy, reduce costs and save lives."  
Published ahead of print under the title "A Stewardship Approach to
Optimize Antimicrobial Therapy Through Use of a Rapid Microarray
Assay on Blood Cultures Positive with Enterococcus species," the
study was performed at University of Florida Health Jacksonville. It
is the first study to evaluate the clinical and economic impact of
using rapid microarray technology on optimizing therapy for
enterococcal bacteria.  
About Verigene(R) Gram-Positive Blood Culture Nucleic Acid Test  
The Verigene(R) Gram-Positive Blood Culture Nucleic Acid (BC-GP) Test
performed using the sample-to-result Verigene System is a
qualitative, multiplexed in vitro diagnostic test for the
simultaneous detection and identification of potentially pathogenic
gram-positive bacteria which may cause bloodstream infection. These
include the following organisms and antibiotic resistance markers:  
Staphylococcus spp.
 Streptococcus spp.
 Listeria spp. 
 Enterococcus
faecalis
 Enterococcus faecium
 Staphylococcus aureus
 Staphylococcus
epidermidis
 Staphylococcus lugdunensis
 Streptococcus pneumoniae 
Streptococcus anginosus group 
 Streptococcus agalactiae 
Streptococcus pyogenes 
And 
mecA gene (methicillin resistance)
 vanA and vanB genes (vancomycin
resistance) 
The Verigene BC-GP Test is performed directly on blood culture
bottles identified as positive by a continuous monitoring blood
culture system and which contain gram-positive bacteria. The Verigene
BC-GP Test is indicated for use in conjunction with other clinical
and laboratory findings to aid in the diagnosis of bacterial
bloodstream infections; however, it is not to be used to monitor
these infections. Sub-culturing of positive blood cultures is
necessary to recover organisms for susceptibility testing, identify
organisms not detected by the Verigene BC-GP Test, differentiate
mixed growth, associate antimicrobial resistance marker genes to a
specific organism, or for epidemiological typing.  
About the Verigene(R) System  
The Verigene System uses core proprietary gold nanoparticle chemistry
to offer highly sensitive, highly specific molecular diagnostic
results through low-cost multiplexing. The Verigene System rapidly
and accurately detects infectious pathogens and drug resistance
markers by mapping the genome of a particular bacterium. Currently,
Verigene assays target infections of the bloodstream, respiratory
tract and gastrointestinal tract. The System also offers additional
capabilities in cancer, cardiovascular disease and autoimmune
disease. The information gathered from Verigene enables clinicians to
identify diseases earlier and make informed patient treatment
decisions more quickly, which may result in improved patient
outcomes, reduced costs, optimized antibiotic therapy, reduced spread
of antibiotic resistance and potentially, saved lives. 
About Nanosphere, Inc.  
Nanosphere is enhancing medicine through targeted molecular
diagnostics that result in earlier disease detection, optimal patient
treatment and improved healthcare economics. The Company's versatile
technology platform, the Verigene(R) System, enables clinicians to
rapidly detect the most complex, costly and deadly infectious
diseases through a low cost and simple-to-use multiplexed diagnostic
test. The combination of this innovative technology and Nanosphere's
customer-driven solutions keeps commitment to the patient at the
forefront of its business. Nanosphere is based in Northbrook, IL.
Additional information is available at http://www.nanosphere.us. 
Except for historical information, the matters discussed in this
press release are "forward-looking statements" and are subject to
risks and uncertainties. Actual results could differ materially from
these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, the
following: (i) Nanosphere's ability to develop commercially viable
products; (ii) Nanosphere's ability to achieve profitability; (iii)
Nanosphere's ability to produce and market its products; (iv)
Nanosphere's ability to obtain regulatory approval of its products;
(v) Nanosphere's ability to protect its intellectual property; (vi)
competition and alternative technologies; and (vii) Nanosphere's
ability to obtain additional financing to support its operations.
Additional risks are discussed in the Company's current filings with
the Securities and Exchange Commission. Although the Company believes
the expectations reflected in such forward-looking statements are
based on reasonable assumptions, it can give no assurance that its
expectations will be attained. The forward-looking statements are
made as of the date of this press release, and we undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. 
Contacts
Investors:
Roger Moody
Chief Financial Officer
Nanosphere, Inc.
847-400-9021
rmoody@nanosphere.us 
Michael Rice
Founding Partner
LifeSci Advisors
646-597-6979
mrice@lifesciadvisors.com 
Media:
Lindsey Saxon
Director of Communications
Nanosphere, Inc.
847-400-9173
lsaxon@nanosphere.us 
Geoff Curtis
Edelman
312-233-1253
geoff.curtis@edelman.com